Pharmacologic Treatment of Hand-, Knee- and Hip-osteoarthritis

Overview

Journal Wien Med Wochenschr

Specialty General Medicine

Date 2013 May 30

PMID 23715933

Citations 3

Authors

Klaus Bobacz

Affiliations

Soon will be listed here.

Abstract

Osteoarthritis (OA) is a joint disease of high prevalence and affects > 90 % of the population, depending on several risk factors. Symptomatic OA is less frequent, but requires an individually tailored therapeutic regimen consisting of non-pharmacological and pharmacological treatment modalities. Pharmacologic therapy, however, is mainly limited to analgetic and anti-inflammatory agents; structure modifying remedies do not exist. The therapeutic approach to hand-, knee- and hip-OA is basically similar and differs only at some minor points. Generally, topical agents or paracetamol are recommended as first-line agents. If unsuccessful oral non-steroidal anti-inflammatory drugs (NSAIDs) or COX-2-selctive inhibitors should be introduced. Tramadol is an option in the case patients will not respond satisfactorily to NSAIDs. Glucosamine and chondroitine sulphate are no longer recommended in knee and hip OA, but chondroitine might be efficient in treating hand OA. Oral NSAIDs should be prescribed with caution due to potential side effects. Opioids are not recommended as their benefits are outweighed by an increased risk for serious adverse events.

Citing Articles

Periarticular hypertonic dextrose vs intraarticular hyaluronic acid injections: a comparison of two minimally invasive techniques in the treatment of symptomatic knee osteoarthritis.

Hosseini B, Taheri M, Pourroustaei Ardekani R, Moradi S, Kazempour Mofrad M Open Access Rheumatol. 2019; 11:269-274.

PMID: 31819680 PMC: 6873954. DOI: 10.2147/OARRR.S215576.

How does surgery compare with advanced intra-articular therapies in knee osteoarthritis: current thoughts.

Wehling P, Moser C, Maixner W Ther Adv Musculoskelet Dis. 2016; 8(3):72-85.

PMID: 27247634 PMC: 4872173. DOI: 10.1177/1759720X16642405.

Thai massage, and Thai herbal compress versus oral ibuprofen in symptomatic treatment of osteoarthritis of the knee: a randomized controlled trial.

Chiranthanut N, Hanprasertpong N, Teekachunhatean S Biomed Res Int. 2014; 2014:490512.

PMID: 25254207 PMC: 4165631. DOI: 10.1155/2014/490512.

References

Nguyen M, Dougados M, Berdah L, Amor B . Diacerhein in the treatment of osteoarthritis of the hip. Arthritis Rheum. 1994; 37(4):529-36. DOI: 10.1002/art.1780370413. View

Haugen I, Englund M, Aliabadi P, Niu J, Clancy M, Kvien T . Prevalence, incidence and progression of hand osteoarthritis in the general population: the Framingham Osteoarthritis Study. Ann Rheum Dis. 2011; 70(9):1581-6. PMC: 3867970. DOI: 10.1136/ard.2011.150078. View

Ragle R, Sawitzke A . Nutraceuticals in the management of osteoarthritis : a critical review. Drugs Aging. 2012; 29(9):717-31. DOI: 10.1007/s40266-012-0006-3. View

Fuchs S, Monikes R, Wohlmeiner A, Heyse T . Intra-articular hyaluronic acid compared with corticoid injections for the treatment of rhizarthrosis. Osteoarthritis Cartilage. 2005; 14(1):82-8. DOI: 10.1016/j.joca.2005.07.016. View

Swindells M, Logan A, Armstrong D, Chan P, Burke F, Lindau T . The benefit of radiologically-guided steroid injections for trapeziometacarpal osteoarthritis. Ann R Coll Surg Engl. 2010; 92(8):680-4. PMC: 3229378. DOI: 10.1308/003588410X12699663905078. View

Rovetta G, Monteforte P, Molfetta G, Balestra V . A two-year study of chondroitin sulfate in erosive osteoarthritis of the hands: behavior of erosions, osteophytes, pain and hand dysfunction. Drugs Exp Clin Res. 2004; 30(1):11-6. View

Zhang W, Moskowitz R, Nuki G, Abramson S, Altman R, Arden N . OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage. 2008; 16(2):137-62. DOI: 10.1016/j.joca.2007.12.013. View

Magnano M, Chakravarty E, Broudy C, Chung L, Kelman A, Hillygus J . A pilot study of tumor necrosis factor inhibition in erosive/inflammatory osteoarthritis of the hands. J Rheumatol. 2007; 34(6):1323-7. View

Nuesch E, Rutjes A, Husni E, Welch V, Juni P . Oral or transdermal opioids for osteoarthritis of the knee or hip. Cochrane Database Syst Rev. 2009; (4):CD003115. DOI: 10.1002/14651858.CD003115.pub3. View

10.

Zhang W, Nuki G, Moskowitz R, Abramson S, Altman R, Arden N . OARSI recommendations for the management of hip and knee osteoarthritis: part III: Changes in evidence following systematic cumulative update of research published through January 2009. Osteoarthritis Cartilage. 2010; 18(4):476-99. DOI: 10.1016/j.joca.2010.01.013. View

11.

Wandel S, Juni P, Tendal B, Nuesch E, Villiger P, Welton N . Effects of glucosamine, chondroitin, or placebo in patients with osteoarthritis of hip or knee: network meta-analysis. BMJ. 2010; 341:c4675. PMC: 2941572. DOI: 10.1136/bmj.c4675. View

12.

Zhang W, Doherty M, Arden N, Bannwarth B, Bijlsma J, Gunther K . EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2004; 64(5):669-81. PMC: 1755499. DOI: 10.1136/ard.2004.028886. View

13.

Shin K, Kim J, Moon K, Yang J, Lee E, Song Y . The efficacy of diacerein in hand osteoarthritis: a double-blind, randomized, placebo-controlled study. Clin Ther. 2013; 35(4):431-9. DOI: 10.1016/j.clinthera.2013.02.009. View

14.

Waseem M, Sadiq S, Gambhir A, Lim J, Maxwell S, Bamford D . Safety and efficacy of intra-articular injection of the hip. Hip Int. 2017; 12(4):378-382. DOI: 10.1177/112070000201200405. View

15.

Heyworth B, Lee J, Kim P, Lipton C, Strauch R, Rosenwasser M . Hylan versus corticosteroid versus placebo for treatment of basal joint arthritis: a prospective, randomized, double-blinded clinical trial. J Hand Surg Am. 2008; 33(1):40-8. DOI: 10.1016/j.jhsa.2007.10.009. View

16.

Reginster J, Badurski J, Bellamy N, Bensen W, Chapurlat R, Chevalier X . Efficacy and safety of strontium ranelate in the treatment of knee osteoarthritis: results of a double-blind, randomised placebo-controlled trial. Ann Rheum Dis. 2012; 72(2):179-86. PMC: 3599139. DOI: 10.1136/annrheumdis-2012-202231. View

17.

Frakes E, Risser R, Ball T, Hochberg M, Wohlreich M . Duloxetine added to oral nonsteroidal anti-inflammatory drugs for treatment of knee pain due to osteoarthritis: results of a randomized, double-blind, placebo-controlled trial. Curr Med Res Opin. 2011; 27(12):2361-72. DOI: 10.1185/03007995.2011.633502. View

18.

van den Bekerom M, Lamme B, Sermon A, Mulier M . What is the evidence for viscosupplementation in the treatment of patients with hip osteoarthritis? Systematic review of the literature. Arch Orthop Trauma Surg. 2007; 128(8):815-23. DOI: 10.1007/s00402-007-0447-z. View

19.

Chan F, Lanas A, Scheiman J, Berger M, Nguyen H, Goldstein J . Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial. Lancet. 2010; 376(9736):173-9. DOI: 10.1016/S0140-6736(10)60673-3. View

20.

Pincus T, Koch G, Lei H, Mangal B, Sokka T, Moskowitz R . Patient Preference for Placebo, Acetaminophen (paracetamol) or Celecoxib Efficacy Studies (PACES): two randomised, double blind, placebo controlled, crossover clinical trials in patients with knee or hip osteoarthritis. Ann Rheum Dis. 2004; 63(8):931-9. PMC: 1755088. DOI: 10.1136/ard.2003.020313. View